TY - JOUR
T1 - European Respiratory Society and European Society of Thoracic Surgeons clinical practice guideline on fitness for curative intent treatment of lung cancer
AU - Brunelli, Alessandro
AU - Hardavella, Georgia
AU - Huber, Rudolf M.
AU - Berghmans, Thierry
AU - Frille, Armin
AU - Rodriguez, Maria
AU - Tietzova, Ilona
AU - Depypere, Lieven
AU - Asteggiano, Riccardo
AU - Batchelor, Tim
AU - Costantini, Adrien
AU - De Ruysscher, Dirk
AU - Durieux, Valerie
AU - Faivre-Finn, Corinne
AU - Ferguson, Mark K.
AU - Langer, Daniel
AU - Marczin, Nandor
AU - Nagavci, Blin
AU - Novoa, Nuria
AU - Pompili, Cecilia
AU - Rawlinson, Janette
AU - Snoeckx, Annemiek
AU - Tonia, Thomy
AU - van Geffen, Wouter H.
AU - Williams, Clare
AU - Caruana, Edward J.
AU - Kabalak, Pinar Akin
AU - Mansmann, Ulrich
AU - Fallet, Vincent
AU - Kauffmann-Guerrero, Diego
AU - Paesmans, Marianne
AU - Tawil, Amani Al
AU - Alhannoush, Nora
AU - Creamer, Andrew W.
AU - Kourouni, Ismini
AU - Blum, Torsten Gerriet
N1 - Funding Information:
Support statement: This work was supported by the European Respiratory Society (TF-2020-07) and the European Society of Thoracic Surgeons. Funding information for this article has been deposited with the Open Funder Registry.
Funding Information:
A lay summary of this document is available at https://europeanlung.org/en/information-hub/guidelines/the-benefits-and-risks-of-lung-cancer-treatments/ Conflict of interest: A. Brunelli reports consultancy fees from AstraZeneca, BMS, Ethicon, MSD, Medtronic and Roche, payment or honoraria for lectures, presentations, manuscript writing or educational events from AstraZeneca, BMS, Ethicon, MSD, Medtronic and Roche, and a leadership role with the European Society of Thoracic Surgeons. R.M. Huber reports participation on a data safety monitoring board or advisory board with Janssen Germany, Merck Germany, Boehringer Ingelheim, Sanofi Germany, Novocure and AstraZeneca, and leadership roles with IASLC and Ludwig-Maximilians-Universit\u00E4t (LMU) ethics committee. T. Berghmans reports consultancy fees from Inhatarget, payment or honoraria for lectures, presentations, manuscript writing or educational events from Bayer, Janssen, Merck, BMS, Daiichi-Sankyo and Roche, support for attending meetings from Takeda and Johnson & Johnson, participation on a data safety monitoring board or advisory board with Bayer, Janssen, Merck, BMS, Daiichi-Sankyo and Roche, and leadership roles with ELCWP (President) and EORTC Lung Cancer Group (Treasurer). A. Frille reports grants from the MetaRot programme supported by the Federal Ministry of Education and Research (BMBF), Germany, Mitteldeutsche Gesellschaft f\u00FCr Pneumologie (MDGP) e.V., Medical Faculty, University of Leipzig and Novartis Foundation, and support for attending meetings from the European Respiratory Society (ERS). M. Rodriguez reports consultancy fees from AstraZeneca and Johnson & Johnson, payment or honoraria for lectures, presentations, manuscript writing or educational events from AstraZeneca, Johnson & Johnson and Intuitive/Abex, support for attending meetings from Intuitive/Abex and Medtronic, and stock (or stock options) with Intuitive and Medtronic. L. Depypere reports consultancy fees from Medtronic and Ethicon, and support for attending meetings from BD. T. Batchelor reports consultancy fees from AstraZeneca and BMS, and payment or honoraria for lectures, presentations, manuscript writing or educational events from Intuitive, Johnson & Johnson and Medtronic. D. De Ruysscher reports grants from AstraZeneca, BMS, Beigene, Philips and Olink, and participation on data safety monitoring or advisory boards with AstraZeneca, BMS, Beigene, Philips, Olink and Eli-Lilly. C. Faivre-Finn reports grants from AstraZeneca, Merck and Elekta, consultancy fees from AstraZeneca, payment or honoraria for lectures, presentations, manuscript writing or educational events from Guy\u2019s and St Thomas NHS Hospital, and support for attending meetings from AstraZeneca, Elekta and Merck. B. Nagavci acted as ERS methodologist (2020\u20132022). N. Novoa reports grants from University of Toronto (lung transplant project) and payment or honoraria for lectures, presentations, manuscript writing or educational events from Medela, Medtronic, AstraZeneca and Johnson & Johnson. C. Pompili reports consultancy fees from Roche, payment or honoraria for lectures, presentations, manuscript writing or educational events from AstraZeneca, BMS and Johnson & Johnson, and support for attending meetings from AstraZeneca and Medela. J. Rawlinson reports support for attending meetings from British Thoracic Oncology Group, EORTC MCCR workshop (with AACR/ESMO), UKIO, Queen Mary University London, UK LC clinical expert group and ERS/ELF, expenses or honoraria related to patient representative work from Nottingham University Hospital/Optellum study, UCL lung cancer PPI group, University of Birmingham ICRB and Oxford cancer PPI group, and is a member of the SOLACE science and ethics board and evaluation group. T. Tonia acts as ERS Methodologist. W.H. van Geffen reports a leadership role with NVALT (Dutch Society of Respiratory Physicians) and is local PI for trials run by his department funded by Roche, Novocure and MSD. E.J. Caruana reports payment or honoraria for lectures, presentations, manuscript writing or educational events from AstraZeneca, AtriCure and MSD. U. Mansmann reports grants from European Community and BMBF, German Government. V. Fallet reports consultancy fees from Pfizer, MSD, BMS, AstraZeneca, Takeda, Janssen, Regeneron, Sanofi and Amgen, payment or honoraria for lectures, presentations, manuscript writing or educational events from Pfizer, MSD, BMS and AstraZeneca, and support for attending meetings from Pfizer, AstraZeneca, IsisMedical, Janssen and Takeda. The remaining authors have no potential conflicts of interest to disclose.
Publisher Copyright:
Copyright © The author(s) 2025.
PY - 2025/11/1
Y1 - 2025/11/1
N2 - A multidisciplinary panel of lung cancer experts with a special interest in functional evaluation of lung cancer patients, and lung cancer patient representatives, has been facilitated by the European Society of Thoracic Surgeons and the European Respiratory Society to provide healthcare professionals with practical and up-to-date recommendations for the assessment of patients' fitness for curative intent treatments for lung cancer. The panel formulated four PICO (population, intervention, comparison and outcomes) questions and seven complementary narrative questions. Both types of questions were assigned to groups of at least two experts. A medical librarian conducted the literature searches, and the authors selected relevant studies based on predefined inclusion criteria. Risk of bias was assessed using the QUIPS (Quality in Prognosis Studies) tool. Data were summarised and the certainty of evidence was assessed with GRADE (Grading of Recommendations, Assessment, Development and Evaluations) and the Evidence to Decisions framework was used to formulate recommendations. A series of multidisciplinary recommendations was formulated about the utilisation of pulmonary function tests, split lung function values, exercise tests, cardiologic testing, and the role of prehabilitation, sublobar resections, risk scores and comorbidities in selecting patients for curative intent treatment.
AB - A multidisciplinary panel of lung cancer experts with a special interest in functional evaluation of lung cancer patients, and lung cancer patient representatives, has been facilitated by the European Society of Thoracic Surgeons and the European Respiratory Society to provide healthcare professionals with practical and up-to-date recommendations for the assessment of patients' fitness for curative intent treatments for lung cancer. The panel formulated four PICO (population, intervention, comparison and outcomes) questions and seven complementary narrative questions. Both types of questions were assigned to groups of at least two experts. A medical librarian conducted the literature searches, and the authors selected relevant studies based on predefined inclusion criteria. Risk of bias was assessed using the QUIPS (Quality in Prognosis Studies) tool. Data were summarised and the certainty of evidence was assessed with GRADE (Grading of Recommendations, Assessment, Development and Evaluations) and the Evidence to Decisions framework was used to formulate recommendations. A series of multidisciplinary recommendations was formulated about the utilisation of pulmonary function tests, split lung function values, exercise tests, cardiologic testing, and the role of prehabilitation, sublobar resections, risk scores and comorbidities in selecting patients for curative intent treatment.
U2 - 10.1183/13993003.00156-2025
DO - 10.1183/13993003.00156-2025
M3 - Article
SN - 0903-1936
VL - 66
JO - European Respiratory Journal
JF - European Respiratory Journal
IS - 5
M1 - 2500156
ER -